BridgeMD
Tests treatment safety and results for Gaucher Disease Type I
Official title A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
ClinicalTrials.gov ID: NCT06162338
What this study is testing
What is LY-M001 Injection?
LY-M001 Injection is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for gaucher disease type i.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of LY-M001 injection.This study mainly includes the main study stage and the long-term follow-up study stage.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Age ≥ 18 years and ≤ 60 years, male or female.
- The people should fully understand the purpose, nature and method of this study as well as possible adverse reactions, and sign the informed consent...
- Patients with GD1 who have confirmed double mutations in the Gba1 allele by laboratory testing and meet the standard for clinical diagnosis of...
- The people were type I patients with Gaucher disease. Patients with type I Gaucher disease who had received specific treatment in the past required 5...
- Negative pregnancy test for female people of childbearing potential 6.6.The subject and his/her partner have no plans to have children during the...
You likely can't join if
- AAV8 neutralizing antibody is strongly positive.
- Patients with clinically suspected Gaucher disease type II (GD2) or Gaucher disease type III (GD3).
- Active and progressive bone disease that is expected to require surgical treatment within the next 6 months.
- Subject has idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), thrombocytopenia, anemia, hepatomegaly...
- Treatment or disposition of an investigational drug or investigational device for another clinical investigation within 28 days or 5 half-lives (only...
- Evidence of clinically significant liver disease, fragile liver, or history of hepatotoxin exposure, meeting at screening, but not limited to, any of...
See the full eligibility criteria
- Age ≥ 18 years and ≤ 60 years, male or female.
- The people should fully understand the purpose, nature and method of this study as well as possible adverse reactions, and sign the informed consent form (ICF) voluntarily.
- Patients with GD1 who have confirmed double mutations in the Gba1 allele by laboratory testing and meet the standard for clinical diagnosis of Gaucher disease (i.e., reduced GCase enzyme activity to less than 30% of...
- The people were type I patients with Gaucher disease. Patients with type I Gaucher disease who had received specific treatment in the past required 5 half-lives of elution
- Negative pregnancy test for female people of childbearing potential 6.6.The subject and his/her partner have no plans to have children during the screening period and within 6 months after the end of the study, and...
- AAV8 neutralizing antibody is strongly positive.
- Patients with clinically suspected Gaucher disease type II (GD2) or Gaucher disease type III (GD3).
- Active and progressive bone disease that is expected to require surgical treatment within the next 6 months.
- Subject has idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), thrombocytopenia, anemia, hepatomegaly, splenomegaly, and/or osteoporosis unrelated to Gaucher disease as judged by the...
- Treatment or disposition of an investigational drug or investigational device for another clinical investigation within 28 days or 5 half-lives (only for drugs), whichever is longer, prior to Screening.
- Evidence of clinically significant liver disease, fragile liver, or history of hepatotoxin exposure, meeting at screening, but not limited to, any of the following:
- Progressive hepatomegaly and greater than 3 times normal volume.
- History of stage 2 or greater liver fibrosis.
- AST, ALT or TBIL greater than 1.5 times the upper limit of normal (ULN).
- History of alcohol or drug abuse within the previous 2 years.
- Hepatitis B surface antigen (HBsAg) positive, and hepatitis B virus DNA positive (HBV-DNA \> 103 copies/mL); or taking hepatitis B virus drugs (such as interferon, lamivudine, adefovir and entecavir); or hepatitis C...
- Human immunodeficiency virus (HIV) antibody positive or Treponema pallidum antibody positive.
- Severe hyperlipidemia (triglycerides \> 1000 mg/dL).
- Uncontrolled concomitant disease or infectious disease (need to be judged by the investigator based on clinical practice).
- Subject had undergone splenectomy and were scheduled to undergo splenectomy during the study period.
- Karnofsky score (KPS) \< 70.
- The subject has received or plans to receive bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation, kidney...
- Subject has received erythropoietin, transfusion, or red blood cell transfusion within 3 months prior to screening ;or platelet transfusion within 1 month prior to screening.
- Clinically diagnosed or significant cardiovascular disease as judged by the investigator (e.g., New York Heart Association [NYHA] class ≥ 3 heart failure).
- Hypersensitivity to any component of LY-M001 Injection.
- Previous treatment with any type of gene therapy or cell therapy.
- Use of systemic immunosuppressive agents or steroid therapy other than those required by the protocol for prophylactic administration within 3 months prior to dosing.
- History of cancer within 5 years of screening, except for completely resected non-melanoma skin cancer, non-metastatic prostate cancer, and completely treated ductal carcinoma in situ.
- Has received a live attenuated vaccine within 4 months prior to screening or plans to receive a live attenuated vaccine during the clinical trial.
- Other conditions that, in the opinion of the investigator, make the subject unsuitable for the study.
The study team makes the final eligibility decision.
Where it's taking place
- Hanzhou, Zhejiang, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hanzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.